| Biomarker ID | 356 |
| PMID | 18559597 |
| Year | 2008 |
| Biomarker | Urokinase-type plasminogen activator (uPA) |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: (Rate Ratio: 3.21); Multivariate: (Rate Ratio: 2.50) |
| Effect on Pathways | Pathways Include:-Beta-3 integrin cell surface interactions, Integrin beta-5 pathway, Alpha-V beta-3 integrin/OPN pathway,Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling, Integrin beta-2 pathway |
| Experiment | Biochemical Recurrence Vs no Recurrence in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 423 patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | Univariate: Concordance Index: 68.5; Multivariate: Concordance Index: 74.2 |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | enzyme immunoassays |
| Clinical | No |
| Remarks | Univariate Analysis. Biochemical recurrence was defined as a sustained elevation, on two or more occasions, of serum total prostate-specific antigen >0.2 ng/mL |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | PLAU |